<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158012">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01823393</url>
  </required_header>
  <id_info>
    <org_study_id>9026</org_study_id>
    <nct_id>NCT01823393</nct_id>
  </id_info>
  <brief_title>Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure</brief_title>
  <acronym>HEPAVALV</acronym>
  <official_title>Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess if the non use of heparin sodium during balloon aortic valvuloplasty reduces
      serious complications due to the procedure, by decreasing the rate of vascular and
      hemorrhagic complications without increasing the rate of ischeamic events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of serious complication : vascular, hemorrhagic or ischaemic complication</measure>
    <time_frame>Up to10 days after the valvuloplasty (D1-D10 after the intervention)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of any non serious complication directly associated with the procedure (vascular, hemorrhagic or ischaemic complication)</measure>
    <time_frame>up to30 days after the valvuloplasty (until D30 after intervention)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Non serious complication is complication directly associated with the valvuloplasty which could be vascular complications medically treated (compression), BARC 2 hemorrhage, general procedure complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of a serious complication : vascular, hemorrhagic or ischaemic complication</measure>
    <time_frame>up to 30 days after valvuloplasty</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Aortic Stenosis, Non-rheumatic</condition>
  <arm_group>
    <arm_group_label>Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of unfractionated heparin (50 IU / kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>without heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure</description>
    <arm_group_label>Heparin</arm_group_label>
    <other_name>Unfractioned heparin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl</intervention_name>
    <description>valvuloplasty is performed without heparin (placebo injection)</description>
    <arm_group_label>NaCl</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  be over 18

          -  carry a tight and symptomatic aortic stenosis

          -  have an indication for a ballon aortic valvuloplasty

          -  Subject have signed his written informed consent

        Exclusion Criteria:

          -  Have an absence of femoral surgical approach

          -  have a criticial hemodynamic state, considered as outdrove for the treatment

          -  have a severe aortic failure

          -  allergia to heparin

          -  contraindication to heparin or/and local anaesthetic

          -  be treted by low molecular weight heparin in less than 12 hoursbefore the
             intervention or by standard heparin in less than 4 hours before the valvulopasty

          -  have a tight but not symptomatic aortic stenosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florence Leclercq, PU PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UH Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>claire chauveton</last_name>
      <phone>0467330924</phone>
      <email>c-chauveton@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Florence Leclercq, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine Delseny, Interne</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Christophe Macia, PU PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Gervasoni, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 29, 2013</lastchanged_date>
  <firstreceived_date>March 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>balloon aortic valvuloplasty indication</keyword>
  <keyword>heparin</keyword>
  <keyword>hemorrhagic</keyword>
  <keyword>ischemic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
